GeoVax Labs to Outline Clinical Progress and Strategic Priorities at Major Healthcare Conferences

GeoVax Labs, Inc. announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026. During these premier investor forums, GeoVax leadership will highlight the company's 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026. The presentation will cover key clinical catalysts, regulatory milestones, and business development related to multiple programs and initiatives that could significantly impact patient care and public health preparedness.

The company will provide updates on CM04S1, its next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. This program is particularly important as it targets high-risk and immunocompromised populations for whom current authorized COVID-19 vaccines may be insufficient. The presentation will include clinical status, translational data, and regulatory pathways for these vulnerable patient groups. For oncology, GeoVax will discuss Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company will present translational and clinical data supporting development in head and neck cancer and other high-value solid tumor indications.

GeoVax will also provide updates on its GEO-MVA vaccine targeting Mpox and smallpox, including regulatory progress, clinical strategy, and potential registration pathways supporting both civilian and biodefense use. Based on recent EMA regulatory guidance, the company anticipates progressing directly to a Phase 3 clinical evaluation for this vaccine, omitting Phase 1 and Phase 2 trials. This regulatory pathway could accelerate development of important biodefense capabilities. The company will highlight advancements in its manufacturing platform, specifically continuous cell-line manufacturing that enables scalable, resilient, and domestic vaccine production. This manufacturing capability is crucial for ensuring vaccine supply chain security and rapid response capabilities during public health emergencies.

David Dodd, Chairman and CEO of GeoVax Labs, will present on January 13, 2026, at 2:30 pm PST at the Hilton Union Square in San Francisco. The presentation will be webcast live and may be accessed through the Events & Presentations section of the company's website at https://www.geovax.com. Management will also host one-on-one investor and partner meetings throughout the conference to discuss GeoVax's progress across its diverse pipeline. The company's participation in these conferences represents an important opportunity to communicate its strategic direction and clinical progress to the investment community and potential collaborators.

GeoVax's presentation matters because the company is addressing critical unmet medical needs in both infectious diseases and oncology. Their COVID-19 vaccine program specifically targets immunocompromised patients who represent a vulnerable population with limited protection from current vaccines. The oncology program addresses solid tumors that often have poor treatment outcomes, while the Mpox/smallpox vaccine has implications for both public health preparedness and national security. The manufacturing advancements could enhance vaccine production capabilities and supply chain resilience. These developments collectively represent significant potential advancements in medical science with implications for patient care, public health infrastructure, and biodefense capabilities.